← back to search

Jeffrey S. Abrams

National Institutes of Health · US
Area of research
Cancer Research · Public Health, Environmental and Occupational Health
Research interest
Research interests include Breast Cancer Treatment Studies, Ethics in Clinical Research, Cancer Genomics and Diagnostics, and Statistical Methods in Clinical Trials.
h-index
46
citations
13,843
works
182
NIH funding
primary concept
Medicine
email

Recent publications

Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC).
2021cited by 21position: contributordoi
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).
2020cited by 215position: contributordoi
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
JNCI: Journal of the National Cancer Institute 2020cited by 186position: contributordoi
Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial
JNCI Journal of the National Cancer Institute 2020cited by 114position: middledoi
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
New England Journal of Medicine 2019cited by 547position: middledoi
Nivolumab Is Effective in Mismatch Repair–Deficient Noncolorectal Cancers: Results From Arm Z1D—A Subprotocol of the NCI-MATCH (EAY131) Study
Journal of Clinical Oncology 2019cited by 170position: middledoi
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy
JAMA Oncology 2019cited by 164position: middledoi
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307
JNCI Journal of the National Cancer Institute 2019cited by 76position: middledoi
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
New England Journal of Medicine 2018cited by 2,351position: middledoi
Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400
Clinical Cancer Research 2015cited by 239position: middledoi
ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non–Small Cell Lung Cancer
Clinical Cancer Research 2015cited by 121position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 3 papers (2020–2021)Larry Rubinstein · National Institutes of Health3 papers (2019–2020)James A. Zwiebel · National Cancer Institute3 papers (2019–2020)Everett E. Vokes · University of Illinois Chicago2 papers (2015–2015)Stanley R. Hamilton · City Of Hope National Medical Center2 papers (2019–2020)Edith P. Mitchell · Sidney Kimmel Cancer Center2 papers (2019–2020)Suresh S. Ramalingam · Emory University2 papers (2015–2015)Lisa M McShane · National Cancer Institute2 papers (2020–2020) · 2 papers (2020–2020) · 2 papers (2020–2021) · 2 papers (2020–2020)David R. Gandara · Comprehensive Blood & Cancer Center2 papers (2015–2015)Shakun Malik · National Cancer Institute2 papers (2015–2015)Alice P. Chen · Massachusetts Institute of Technology2 papers (2019–2020)Lawrence H. Schwartz · Columbia University Irving Medical Center1 papers (2015–2015)Caroline C. Sigman · VA Boston Healthcare System1 papers (2015–2015)Nilofer S. Azad · Bloomberg (United States)1 papers (2019–2019) · 1 papers (2019–2019) · 1 papers (2015–2015)Shaker R. Dakhil · Cancer Center of Kansas1 papers (2019–2019)